Momenta to pay $35m to end enoxaparin class-action suit

12-12-2019

Rory O'Neill

Momenta to pay $35m to end enoxaparin class-action suit

Sebastian Kaulitzki / Shutterstock.com

Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.


Momenta Pharmaceuticals, US Securities and Exchange Commission, Sandoz, Sanofi, enoxaparin, blood clots

LSIPR